The glucagon-like peptide-1 receptor agonists (GLP-1 RA) semaglutide and liraglutide have favorable effects on cardiovascular outcomes in patients with type 2 diabetes mellitus, especially among those with a high cardiovascular risk profile.6, 7, 8, 9, 10 The beneficial effects of GLP-1 RA have recently been shown to extend to obese patients without diabetes and those with congestive heart failure.11, 12, 13, 14. This evidence concerns the gene GCG and congestive heart failure.